Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 604
Gene Symbol: BCL6
BCL6
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE The 2016 WHO classification defines diffuse large B-cell lymphoma subtypes based on EBV infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis. 31123031

2020

Entrez Id: 25
Gene Symbol: ABL1
ABL1
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 GeneticVariation BEFREE The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis. 31831854

2020

Entrez Id: 6777
Gene Symbol: STAT5B
STAT5B
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Taken together, we demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis. 31687977

2020

Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. 31719683

2020

Entrez Id: 596
Gene Symbol: BCL2
BCL2
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Taken together, we demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis. 31687977

2020

Entrez Id: 6776
Gene Symbol: STAT5A
STAT5A
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Taken together, we demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis. 31687977

2020

Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. 31719683

2020

Entrez Id: 472
Gene Symbol: ATM
ATM
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 AlteredExpression BEFREE Altogether, our data indicate that T cell-specific restoration of ATM activity or allogeneic hematopoietic stem cell transplantation may prevent lymphomagenesis in A-T patients. 31690822

2020

Entrez Id: 207
Gene Symbol: AKT1
AKT1
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. 31719683

2020

Entrez Id: 1236
Gene Symbol: CCR7
CCR7
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Notably, reduced GATA2 expression suppresses the differentiation but promotes the proliferation of EVI1-expressing leukemic cells, which accelerates EVI1-driven leukemogenesis. 31820561

2020

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. 31719683

2020

Entrez Id: 5914
Gene Symbol: RARA
RARA
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE To investigate the potential functional role of NLS-RARα in leukemogenesis, HL-60 and U937 cell lines were transfected with NLS-RARα lentivirus and negative control (LVNC). 31654721

2020

Entrez Id: 2122
Gene Symbol: MECOM
MECOM
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Notably, reduced GATA2 expression suppresses the differentiation but promotes the proliferation of EVI1-expressing leukemic cells, which accelerates EVI1-driven leukemogenesis. 31820561

2020

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 GeneticVariation BEFREE However, in Tp53 deficient mice, Setd4 deletion did not delay the radiation-induced lymphomagenesis although it accelerated the spontaneous T-lymphomagenesis in non-irradiated mice. 31794893

2020

Entrez Id: 4609
Gene Symbol: MYC
MYC
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 GeneticVariation BEFREE The 2016 WHO classification defines diffuse large B-cell lymphoma subtypes based on EBV infection and oncogenic rearrangements of MYC/BCL2/BCL6 as drivers of lymphomagenesis. 31123031

2020

Entrez Id: 2322
Gene Symbol: FLT3
FLT3
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Advances in the understanding of the complex mechanisms of AML leukemogenesis have led to the development and recent US Food and Drug Administration (FDA) approval of several targeted therapies: midostaurin and gilteritinib targeting activated FLT3, and ivosidenib and enasidenib targeting mutated IDH1/2. 31848884

2020

Entrez Id: 4629
Gene Symbol: MYH11
MYH11
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. 31624376

2020

Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. 31719683

2020

Entrez Id: 4609
Gene Symbol: MYC
MYC
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 AlteredExpression BEFREE Paradoxically, PI3K-AKT activation facilitates MYC-driven lymphomagenesis in mice, and it has been proposed that PI3K-AKT activation is essential for BL. 31719683

2020

Entrez Id: 5079
Gene Symbol: PAX5
PAX5
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE PAX5-plus represents the first BCP-ALL subgroup defined by sequence alterations in contrast to gross chromosomal events and exemplifies how deregulated differentiation (PAX5), impaired cell cycle control (CDKN2A/B) and sustained proliferative signaling (RAS) cooperatively drive leukemogenesis. 30842609

2019

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 AlteredExpression BEFREE <i>MiR-335</i>/<i>ID4</i> dysregulation facilitated leukemogenesis through the activation of PI3K/Akt signaling pathway. 31147526

2019

Entrez Id: 6777
Gene Symbol: STAT5B
STAT5B
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE As mutations in STAT5B, but not STAT5A, have been frequently described in hematopoietic tumors, we used BCR/ABL as model systems to investigate the contribution of STAT5A or STAT5B for leukemogenesis. 30679796

2019

Entrez Id: 4609
Gene Symbol: MYC
MYC
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 AlteredExpression BEFREE Deregulation of the MYC transcription factor is a key driver in lymphomagenesis. 31243099

2019

Entrez Id: 9260
Gene Symbol: PDLIM7
PDLIM7
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 AlteredExpression BEFREE We have focused on the EBV-encoded latent membrane protein-1 (LMP1), a constitutively activated CD40 homologue expressed in almost all EBV-positive DLBCLs and which can disrupt germinal centre (GC) formation and drive lymphomagenesis in mice. 30666658

2019

Entrez Id: 862
Gene Symbol: RUNX1T1
RUNX1T1
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.100 Biomarker BEFREE TAF1 plays a critical role in AML1-ETO driven leukemogenesis. 31664040

2019